<p>Obesity biotech aims to reduce fat while preserving lean mass, with first-in-human studies planned for late 2027. Seventy million dollars, an oversubscribed round and a mechanism that has nothing to do with appetite: Moonwalk Biosciences has just raised its Series B to press ahead with a rather diff</p>